ADVERTISEMENT

Mankind Pharma launches drug to treat black fungus

June 10, 2021 12:55 pm | Updated 12:55 pm IST - New Delhi

The company has launched the drug under the brand name Posaforce 100

Mankind Pharma on Thursday, June 10, 2021, said it has launched Posaconazole Gastro resistant tablets, used to treat black fungus , in the country.

Also read: Alternative form of anti-Black Fungus drug unveiled

The company has launched the drug under the brand name Posaforce 100.

ADVERTISEMENT

“As the cases of black fungus are increasing day by day, the product has been launched to fight against this infection. The drug firm always strives to launch affordable medicines with an endeavour to achieve the best quality standards in the pharmaceutical industry,” Mankind Pharma said in a statement.

The country has seen more than 12,000 cases of deadly black fungus (mucormycosis), so far with Gujarat, Maharashtra, Andhra Pradesh, Madhya Pradesh and Telangana, accounting for the maximum number of cases.

DCGI nod

ADVERTISEMENT

Posaconazole has been found to be a safer and effective drug of choice for the management of the disease. The drug has received approval from the Drug Controller General of India (DCGI), the drug maker noted Besides, AIIMS and ICMR have also recommended use of Posaconazole as an effective option for the management of mucormycosis, it added.

The antifungal drug with minimal potential for nephrotoxicity and excellent tolerability profile has been cleared by the USFDA.

Black fungus commonly occurs in soil, and airborne spores often produce infections.

Life threatening conditions like severe COVID-19 infection; prolonged immune suppression or reduced immunity, uncontrolled diabetes mellitus or haematological malignancies and even open wounds contamination with Mucorales can lead to this infection.

This is a Premium article available exclusively to our subscribers. To read 250+ such premium articles every month
You have exhausted your free article limit.
Please support quality journalism.
You have exhausted your free article limit.
Please support quality journalism.
The Hindu operates by its editorial values to provide you quality journalism.
This is your last free article.

ADVERTISEMENT

ADVERTISEMENT